1-Ethyl-2,2-dimethylpyrrolidine | 89214-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-Ethyl-2,2-dimethylpyrrolidine
• CAS: 89214-93-7
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: GBUNDJORTUZESU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170129899A1

  公开（公告）日：2017-05-11

  This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  该申请涉及式(I)的化合物，或其药用盐或立体异构体，这些化合物是PI3K-γ的抑制剂，对于治疗自身免疫性疾病、癌症、心血管疾病和神经退行性疾病等疾病有用。
• PYRIDO[3,4-B]INDOLES AND METHODS OF USE
  申请人：JAIN Rajendra Parasmal

  公开号：US20110237582A1

  公开（公告）日：2011-09-29

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。描述了吡咯[3,4-b]吲哚，以及包含该化合物的制药组合物和使用该化合物进行多种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Tetracycline Compounds
  申请人：Chen Chi-Li

  公开号：US20120135968A1

  公开（公告）日：2012-05-31

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物或其药学上可接受的盐。结构式I的变量在此定义。同时还描述了包含结构式I化合物的药物组合物及其治疗用途。
• Inhibitors of plasma kallikrein
  申请人：Kalvista Pharmaceuticals Limited

  公开号：US10221161B2

  公开（公告）日：2019-03-05

  The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.

  本发明提供了式 (I) 化合物、包含此类化合物的组合物；此类化合物在治疗中的用途（例如在治疗或预防血浆卡利克瑞因活性涉及的疾病或病症中的用途）；以及用此类化合物治疗患者的方法；其中 R5、R6、R7、R12、R13、A、L、B、n、W、X、Y 和 Z 如本文所定义。
• TETRACYCLINE COMPOUNDS
  申请人：Tetraphase Pharmaceuticals, Inc.

  公开号：EP2427425B1

  公开（公告）日：2017-03-08